increas
appreci
microbiom
composit
affect
treatmentrel
complic
cytotox
chemotherapi
hematopoiet
stem
cell
transplant
hsct
patient
hematolog
malign
includ
infect
gastrointestin
gi
toxic
develop
graftversushost
diseas
gvhd
exampl
sever
studi
establish
associ
gut
microbiota
hsct
outcom
includ
transplantrel
mortal
relaps
rate
overal
surviv
although
term
microbiom
technic
refer
microorgan
nearli
studi
date
focus
role
bacteria
rather
fungi
although
still
markedli
understudi
compar
bacteriom
increas
number
report
link
commens
fungi
mycobiom
health
patient
hematolog
malign
exampl
research
found
patient
colon
candida
sp
develop
significantli
grade
ii
iv
acut
gvhd
gi
gvhd
noncolon
patient
previous
found
mouth
gut
domin
candida
albican
candida
glabrata
prior
mucormycosi
induct
remiss
chemotherapi
similarli
patient
baselin
microbiom
commun
domin
candida
acidur
bacteria
like
develop
oral
candidiasi
antineoplast
treatment
recent
variat
mycobiom
composit
link
treatmentrel
toxic
autolog
hsct
multipl
myeloma
specif
composit
baselin
oral
mycobiom
associ
vomit
well
cultureneg
neutropen
fever
fungal
commun
day
posttransplant
associ
incid
sever
mucos
patient
hematolog
malign
receiv
multipl
type
drug
may
impact
fungal
bacteri
commun
evid
oral
intestin
bacteri
microbiota
human
may
alter
cytotox
chemotherapi
although
effect
fungal
microbiota
less
clear
previous
shown
cytotox
cisplatin
compound
direct
anticandida
activ
also
inhibit
filamentationconid
recent
investig
demonstr
oral
microbiom
disrupt
doxorubicin
chemotherapi
observ
major
chang
composit
mycobiom
moreov
mice
receiv
c
albican
loss
bacteri
divers
show
endogen
overgrowth
organ
enterococcu
stenotrophomona
oral
mucosa
addit
chemotherapi
antimicrobi
therapi
common
practic
patient
popul
impact
mycobiom
composit
exampl
observ
antibiot
antianaerob
activ
affect
oral
fungal
commun
composit
posttransplant
multipl
myeloma
patient
also
bacteremia
fluconazoleresist
candida
associ
exposur
sever
differ
antimicrobi
includ
carbapenem
clindamycin
colistin
long
known
antibacteri
agent
promot
fungal
growth
via
indirect
effect
mani
promot
candida
colon
given
member
mycobiom
interact
bacteriom
way
benefici
neutral
detriment
host
aim
determin
chang
oral
mycobiom
fungusbacterium
relationship
set
leukemia
remissioninduct
chemotherapi
ric
given
patient
typic
receiv
combin
antibiot
antifung
cytotox
chemotherapi
given
key
role
candida
health
oropharynx
oral
microaspir
common
patholog
mechan
bacteri
pneumonia
sever
infect
ric
patient
popul
focus
oral
mycobiom
connect
oral
bacteriom
patient
demograph
clinic
data
shown
tabl
includ
approxim
equal
number
male
femal
mean
age
year
genu
level
abund
genu
observ
across
time
point
malassezia
follow
candida
saccharomyc
fusarium
cladosporium
similar
core
set
oral
mycobiom
taxa
previous
identifi
among
healthi
individu
includ
candida
cladosporium
saccharomycetal
aspergillu
fusarium
cryptococcu
malassezia
although
aspergillu
seen
least
one
oral
sampl
patient
detect
abund
longitudin
sampl
addit
among
sampl
detect
abund
aspergillu
median
rel
abund
interquartil
rang
iqr
observ
interest
given
aspergillu
primari
caus
invas
mold
infect
among
patient
hematolog
malign
abund
top
ten
abund
genera
show
signific
intrapati
interpati
variabl
across
time
fig
howev
appear
homogen
within
patient
across
time
mean
intrapati
braycurti
dissimilar
sampl
within
patient
among
cohort
member
versu
averag
interpati
valu
sampl
across
time
point
consist
anoth
studi
analyz
oral
mycobiom
stabil
day
reveal
high
interindividu
divers
yet
indic
intraindividu
stabil
use
result
principalcoordin
analysi
pcoa
shown
fig
found
distinct
group
patient
time
point
base
braycurti
dissimilar
next
sought
describ
oral
mycobiom
chang
cours
ric
mixedeffect
model
found
mycobiom
significantli
chang
time
p
shannon
p
simpson
p
fig
unlik
previous
note
bacteriom
divers
decreas
baselin
neutrophil
recoveri
among
leukemia
patient
receiv
ric
next
sought
determin
mycobiom
profil
associ
clinic
variabl
among
patient
cohort
includ
chemotherapeut
antimicrobi
administr
sampl
patient
highintens
chemotherapi
receiv
lowintens
chemotherapi
tabl
major
patient
receiv
fludarabinebas
regimen
major
regimen
fia
idarubicin
cytarabin
fludarabin
flagida
fludarabin
idarubicin
granulocytecolonystimul
factor
twentyeight
percent
patient
receiv
nonfludarabin
highintens
regimen
typic
includ
cia
idarubicin
cytarabin
clofarabin
base
ia
idarubicin
cytarabin
base
clia
cladribin
idarubicin
cytarabin
base
regimen
patient
also
receiv
hypomethylatorbas
treatment
decitabin
azacitadin
lowdos
therapi
includ
ldac
lowdos
antimetabolit
cytarabin
base
regimen
given
uneven
sampl
time
time
neutrophil
recoveri
among
patient
evalu
mycobiom
structur
composit
baselin
midpoint
later
time
point
common
among
patient
patient
receiv
lowintens
ric
significantli
higher
mycobiom
patient
receiv
highintens
ric
observ
oper
taxonom
unit
otu
p
shannon
p
see
fig
supplement
materi
although
kruskalw
test
indic
rel
abund
five
abund
fungal
genera
significantli
differ
four
differ
chemotherapi
subtyp
singl
time
point
see
tabl
supplement
materi
determin
chemotherapi
subtyp
significantli
associ
rel
abund
specif
taxa
time
specif
patient
receiv
highintens
chemotherapi
experienc
decreas
malassezia
abund
time
p
fig
effect
seen
taxa
analyz
data
shown
knowledg
chang
oral
mycobiom
occur
result
chemotherapi
studi
regard
role
chemotherapyinduc
mucos
set
doxorubicinbas
chemotherapi
mice
human
patient
although
author
expect
chemotherapi
affect
oral
mycobiom
major
chang
composit
fungal
commun
observ
thu
studi
would
first
show
specif
chang
oral
mycobiom
associ
chemotherapeut
intens
type
next
sought
determin
antimicrobi
administr
result
signific
mycobiom
chang
ric
aml
examin
three
primari
empir
broadspectrum
antibiot
receiv
cohort
carbapenem
cephalosporin
piperacillintazobactam
found
patient
administ
least
one
three
broadspectrum
antimicrobi
patient
receiv
one
broadspectrum
antibiot
prior
neutrophil
recoveri
receiv
carbapenem
cephalosporin
piperacillintazobactam
also
evalu
three
primari
treatment
antifung
consist
echinocandin
amphotericin
b
triazol
patient
administ
least
one
three
antifung
receiv
azol
echinocandin
amphotericin
b
analyz
later
time
point
ric
given
antimicrobi
analyz
administ
latest
time
point
common
among
patient
surprisingli
signific
associ
rel
abund
top
abund
fungal
taxa
time
point
receipt
specif
antimicrobi
tabl
howev
amphotericin
b
seem
signific
effect
composit
oral
fungal
commun
time
patient
receiv
amphotericin
b
experienc
increas
rel
abund
fusarium
time
p
fig
biolog
plausibl
observ
inasmuch
fusarium
speci
associ
high
amphotericin
b
mic
amphotericin
b
signific
effect
rel
abund
taxa
time
light
complex
interplay
fungal
popul
opportunist
bacteri
pathogen
sought
determin
relationship
mycobiom
infect
aml
patient
ric
total
patient
microbiolog
defin
infect
posit
bacteri
cultur
includ
mostli
bacteremia
urinari
tract
infect
tabl
also
consid
patient
clinic
defin
infect
pneumonia
cellul
absenc
posit
cultur
analysi
analyz
three
major
time
point
found
rel
abund
candida
significantli
higher
patient
contract
microbiolog
clinic
defin
infect
prior
neutrophil
recoveri
p
significantli
higher
rel
abund
fusarium
p
develop
infect
prior
neutrophil
recoveri
fig
result
corrobor
use
lefs
linear
discrimin
analysi
effect
size
algorithm
candida
differenti
abund
among
patient
develop
infect
prior
neutrophil
recoveri
fig
fusarium
abund
among
patient
infect
fig
statist
associ
observ
genera
three
time
point
data
shown
crossdomain
associ
network
construct
use
match
bacteri
fungal
microbiom
sampl
n
three
spieceasi
spars
invers
covari
estim
ecolog
associ
infer
network
show
vast
differ
intra
interkingdom
connect
time
point
highlight
dynam
natur
bacteri
fungal
interact
induc
chang
commun
ric
fig
averag
node
degre
standard
deviat
sd
sd
sd
respect
baselin
observ
one
crossdomain
connect
ramularia
haemophilu
two
bacteri
connect
fusobacterium
alloprevotella
enterococcu
rothia
two
fungal
connect
malassezia
candida
fungi
sp
unknownunidentifi
fungal
genu
malassezial
sp
network
contain
nine
crossdomain
connect
cladosporium
stenotrophomona
aspergillu
fusobacterium
aspergillu
alloprevotella
saccharomyc
prevotellacea
saccharomyc
neisseria
meyerozyma
acinetobact
meyerozyma
stenotrophomona
pichia
campylobact
ramularia
capnocytophaga
four
bacteri
connect
acinetobact
stenotrophomona
prevotellacea
prevotella
alloprevotella
prevotellacea
prevotellacea
prevotella
three
fungal
connect
cladosporium
pichia
cordycep
fungi
sp
candida
malassezia
latest
time
point
analyz
observ
seven
crossdomain
connect
alternaria
streptococcu
cladosporium
rothia
saccharomyc
mycoplasma
sporidiobolal
sp
pseudomona
fungi
sp
lactobacillu
fungi
sp
actinomyc
starmerella
veillonella
two
bacteri
connect
enterococcu
prevotella
prevotellacea
leptotrichia
intrakingdom
interkingdom
interact
previous
observ
specif
malassezia
candida
often
coisol
infecti
sampl
skin
infect
onychomycosi
knowledg
cooccurr
shown
oral
caviti
interestingli
found
neg
correl
malassezia
candida
oral
caviti
studi
oral
microbiom
hiv
patient
versu
uninfect
individu
found
cladosporidium
rothia
posit
correl
uninfect
individu
observ
cooccurr
treat
leukemia
patient
also
individu
uninfect
hiv
neg
correl
aspergillu
prevotella
observ
crossdomain
connect
cooccurr
studi
author
observ
cocolon
cladosporidium
pichia
uninfect
individu
fungal
relationship
detect
addit
saw
bacteri
cooccurr
relationship
prevotellacea
leptotrichia
also
observ
subject
apic
periodont
subject
halitosi
well
healthi
individu
one
connect
overlap
two
network
interestingli
howev
time
point
show
moredepend
connect
multipl
node
link
time
point
increas
connect
overal
previous
report
loss
bacteri
divers
time
among
patient
includ
analys
suggest
either
loss
bacteri
divers
chang
oral
environ
condit
chemotherapeut
antimicrobi
pressur
affect
bacteriumfungu
interplay
may
potenti
result
clinic
consequ
organ
typic
interact
would
inhabit
nich
could
potenti
acut
consequ
function
metabolit
genet
exchang
alter
virul
pathogen
immun
statu
host
fungusbacterium
interact
oral
caviti
diseas
healthi
individu
name
candidabacterium
interact
intens
studi
howev
interact
bacteria
known
fungal
inhabit
oral
caviti
yet
describ
thu
impact
fungusbacterium
interact
oral
caviti
overal
health
complet
understood
although
exploratori
studi
rel
small
sampl
size
assess
oral
sampl
data
shown
still
highlight
dynam
natur
mycobiom
bacteriom
commun
interact
cours
ric
unfortun
studi
design
includ
inform
diet
metabol
milieu
eg
relev
comorbid
diabet
oral
health
inform
includ
oropharyng
candidiasi
occurr
mucos
clinic
factorsoutcom
could
potenti
account
heterogen
seen
within
data
might
also
associ
specif
mycobiom
bacteriom
compositionsrelationship
despit
includ
comprehens
record
clinic
covari
abl
determin
specif
chang
mycobiom
commun
structur
appear
clinic
consequ
term
bacteri
infect
moreov
interkingdom
dynam
like
driven
chang
mycobiom
due
chemotherapi
intens
subtyp
well
bacteriom
chang
driven
antibiot
exposur
although
report
highlight
underappreci
complex
dynam
natur
crosskingdom
interact
occur
time
result
stress
chemotherapi
antibiot
therapi
data
limit
use
marker
gene
analysi
rrna
gene
intern
transcrib
spacer
sequenc
identifi
bacteriumfungu
dynam
target
gene
analysi
limit
abil
differenti
individu
taxa
specif
lower
taxonom
level
speci
level
although
abil
assembl
differenti
fungal
read
wholegenom
level
current
restrict
number
fungal
genom
avail
public
databas
inform
could
vastli
improv
futur
via
shotgun
metagenom
sequenc
particularli
regard
function
pathway
analysi
altern
approach
would
layer
metabolom
metaproteom
understand
function
consequ
bacteri
fungal
chang
well
interkingdom
metabol
pathway
interact
howev
method
data
integr
shotgun
metagenom
metabolom
data
particularli
regard
crossdomain
network
still
infanc
provid
first
longitudin
analysi
oral
mycobiom
patient
acut
leukemia
combin
parallel
oral
bacteriom
data
incorpor
fungal
analys
microbiom
studi
may
help
improv
mechanist
understand
commens
flora
impact
clinic
outcom
data
suggest
simultan
mycobiom
bacteriom
longitudin
analys
may
add
addit
insight
order
fulli
understand
microbiom
impact
infecti
risk
immunocompromis
patient
anticip
data
inspir
futur
studi
aim
elucid
relationship
cancer
treatment
set
pilot
exploratori
studi
collect
oral
buccal
swab
sampl
n
newli
diagnos
adult
aml
patient
undergo
ic
md
anderson
cancer
center
mdacc
houston
tx
septemb
august
oral
sampl
accompani
rrna
gene
sequenc
deriv
previous
report
cohort
studi
protocol
approv
mdacc
institut
review
board
studi
conduct
complianc
declar
helsinki
written
inform
consent
obtain
particip
enrol
buccal
swab
collect
swab
insid
cheek
time
side
use
catchal
sampl
collect
swab
epicentr
swab
tip
place
steril
cryovial
maintain
dna
extract
collect
sampl
patient
perform
baselin
continu
approxim
everi
h
stop
upon
neutrophil
recoveri
clinic
data
includ
antibiot
antifung
administr
chemotherapi
subtyp
infect
statu
extract
electron
medic
record
infect
prior
neutrophil
recoveri
classifi
microbiolog
defin
infect
mdi
clinic
defin
infect
cdi
use
establish
guidelin
patient
categor
receiv
nonfludarabinebas
highintens
regimen
ii
highintens
fludarabinecontain
regimen
iii
lowintens
hypomethylatingagentbas
therapi
iv
lowintensitylowdos
cytarabinebas
regimen
microbi
dna
extract
oral
swab
use
mo
bio
powersoil
dna
isol
kit
protocol
describ
previous
perform
sequenc
subset
patient
first
sequenti
patient
enrol
studi
avail
residu
sampl
previous
character
microbiom
use
rrna
gene
sequenc
intern
transcrib
spacer
region
amplifi
oral
swab
dna
use
primer
describ
previous
primer
includ
illumina
adapt
linker
sequenc
revers
primer
also
contain
uniqu
golay
barcod
amplicon
sequenc
use
illumina
miseq
platform
pairedend
protocol
read
pair
demultiplex
base
uniqu
barcod
read
merg
filter
use
default
set
usearch
sequenc
cluster
oper
taxonom
unit
otu
similar
cutoff
use
upars
pipelin
chimera
remov
use
usearch
uchim
otu
align
sequenc
ncbi
genbank
plant
unit
databas
abund
data
recov
map
demultiplex
read
upars
otu
custom
script
develop
center
metagenom
microbiom
research
baylor
colleg
medicin
use
construct
otu
tabl
unmap
ident
coverag
otu
manual
analyz
blastn
perform
filter
includ
sampl
correspond
clinic
data
match
data
sampl
obtain
analys
principalcoordin
analysi
pcoa
plot
produc
use
braycurti
distanc
mixedeffect
model
appli
determin
time
signific
predictor
random
intercept
patient
includ
kruskalw
test
perform
compar
taxon
abund
data
chemotherapi
subtyp
group
associ
test
focus
top
five
abund
fungal
genera
base
averag
abund
candida
cladosporium
fusarium
malassezia
saccharomyc
similarli
mannwhitney
test
perform
compar
alphadivers
data
taxon
abund
data
correspond
chemotherapi
intens
high
versu
low
use
amphotericin
b
ye
versu
infect
statu
ye
versu
linear
discrimin
analysi
effect
size
lefs
algorithm
use
test
whether
taxon
abund
predict
infect
statu
lefs
algorithm
run
use
galaxi
modul
default
set
mixedeffect
model
use
determin
whether
taxon
abund
significantli
chang
time
analys
base
model
perform
center
log
ratio
clr
transform
rel
abund
data
address
composit
characterist
data
model
contain
follow
variabl
time
point
variabl
interest
interact
two
account
repeat
measur
random
intercept
patient
includ
model
analysi
varianc
anova
ftest
appli
determin
whether
time
variabl
interest
significantli
associ
statist
analys
perform
part
studi
exploratori
natur
gener
p
valu
less
consid
signific
analys
across
mycobiom
comput
falsediscoveryr
fdr
adjust
p
valu
provid
supplement
tabl
data
analysi
visual
perform
use
r
mainli
use
function
r
packag
phyloseq
spieceasi
use
construct
crossdomain
microbi
network
genu
level
bacteria
fungi
tabl
list
bacteri
fungal
genera
data
correspond
time
point
separ
statist
sound
method
longitudin
analysestrend
underdevelop
microbiom
network
analys
aim
analyz
sampl
baselin
prior
chemotherapi
antimicrobi
administr
time
point
chemotherapi
administr
time
point
antimicrobi
administr
signific
sampl
dropout
given
alreadi
small
sampl
size
last
time
point
retain
sampl
addit
patient
receiv
broadspectrum
antibiot
receiv
least
one
type
broadspectrum
antibiot
otu
tabl
taxa
includ
network
analysi
mean
abund
greater
sampl
bacteri
taxa
fungal
taxa
repres
sampl
bacteri
taxa
fungal
taxa
contain
sampl
bacteri
taxa
fungal
taxa
sparsiti
paramet
set
valu
correspond
set
verifi
stabil
result
singl
valu
also
examin
sensit
across
multipl
valu
found
network
sensit
choic
rrna
gene
sequenc
deposit
ncbi
sequenc
read
archiv
http
wwwncbinlmnihgovsra
bioproject
identifi
id
wherea
sequenc
submit
bioproject
id
author
could
make
bioproject
record
avail
time
paper
public
due
circumst
relat
pandem
made
access
soon
possibl
public
